Romosozumab reduces fracture risk in postmenopausal women with osteoporosis
Researchers find that the drug can be an effective treatment for women who are susceptible to fracture.
Source: Prof P Motta / Science Photo Library
Around 40% of women with postmenopausal osteoporosis will go on to sustain one or more fragility fractures.
Researchers investigated the effect of romosozumab, a monoclonal antibody, in a randomised controlled trial of 7,180 postmenopausal women aged 55–85 years old. All participants had abnormally low bone mineral density scores in their spine, hip and femoral neck and were assigned to either a monthly dose of romosozumab, or placebo.
After one year it was found that romosozumab was associated with an 83% lower risk of clinical vertebral fracture at 12 months, compared with placebo. The effect of the drug on the risk of vertebral fracture was found to be rapid, with only two additional vertebral fractures, of a total of 16, occurring in the second 6 months of therapy.
Presenting at the Annual European Congress of Rheumatology (14 June 2017), the authors concluded that romosozumab could be used as an effective treatment for postmenopausal women with osteoporosis who are at increased risk of fracture.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203555
Recommended from Pharmaceutical Press